|
1
|
Curry RC, Dahiya S, Alva Venur V, Raizer
JJ and Ahluwalia MS: Bevacizumab in high-grade gliomas: Past,
present, and future. Expert Rev Anticancer Ther. 15:387–397. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang KY: Specificity protein 1-modulated
superoxide dismutase 2 enhances temozolomide resistance in
glioblastoma, which is independent of O6-methylguanine-DNA
methyltransferase. Redox Biol. 13:655–664. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumthekar P: A phase II trial of arsenic
trioxide and temozolomide in combination with radiation therapy for
patients with malignant gliomas. J Neurooncol. 133:589–594. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blakeley JO, Grossman SA, Mikkelsen T,
Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia
Ribas I, Supko JG, et al: Phase I study of iniparib concurrent with
monthly or continuous temozolomide dosing schedules in patients
with newly diagnosed malignant gliomas. J Neurooncol. 125:123–131.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong ET, Timmons J, Callahan A, O'Loughlin
L, Giarusso B and Alsop DC: Phase I study of low-dose metronomic
temozolomide for recurrent malignant gliomas. BMC Cancer.
16:9142016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Messaoudi K, Clavreul A and Lagarce F:
Toward an effective strategy in glioblastoma treatment. Part I:
Resistance mechanisms and strategies to overcome resistance of
glioblastoma to temozolomide. Drug Discov Today. 20:899–905. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakada M, Kita D, Watanabe T, Hayashi Y
and Hamada J: Mechanism of chemoresistance against tyrosine kinase
inhibitors in malignant glioma. Brain Tumor Pathol. 31:198–207.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Klionsky DJ: Autophagy revisited: A
conversation with Christian de Duve. Autophagy. 4:740–743. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohsumi Y: Historical landmarks of
autophagy research. Cell Res. 24:9–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis bybeclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kabeya Y, Mizushima N, Ueno T, Yamamoto A,
Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hart LS, Cunningham JT, Datta T, Dey S,
Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, et al: ER
stress-mediated autophagy promotes Myc-dependent transformation and
tumor growth. J Clin Invest. 122:4621–4634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aoki H, Kondo Y, Aldape K, Yamamoto A,
Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K,
Shinojima N, et al: Monitoring autophagy in glioblastoma with
antibody against isoform B of human microtubule-associated protein
1 light chain 3. Autophagy. 4:467–475. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palumbo S and Comincini S: Autophagy and
ionizing radiation in tumors: The ‘survive or not survive’ dilemma.
J Cell Physiol. 228:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang X, Bai HM, Chen L, Li B and Lu YC:
Reduced expression of LC3B-II and Beclin 1 in glioblastoma
multiforme indicates a downregulated autophagic capacity that
relates to the progression of astrocytic tumors. J Clin Nuronsci.
17:1515–1519. 2010. View Article : Google Scholar
|
|
17
|
Miracco C, Cosci E, Oliveri G, Luzi P,
Pacenti L, Monciatti I, Mannucci S, De Nisi MC, Toscano M,
Malagnino V, et al: Protein and mRNA expression of autophagy gene
Beclin 1 in human brain tumours. Int J Oncol. 30:429–436.
2007.PubMed/NCBI
|
|
18
|
National Pharmacopoeia Committee:
Pharmacopoeia of People's Republic of China, Part 1. The Medicine
Science and Technology Press of China; Beijing: pp. 160–161.
2010
|
|
19
|
Fan X, Zhu JY, Sun Y, Luo L, Yan J, Yang
X, Yu J, Tang WQ, Ma W and Liang HP: Evodiamine inhibits
zymosan-induced inflammation in vitro and in vivo: Inactivation of
NF-κB by inhibiting IκBα phosphorylation. Inflammation.
40:1012–1027. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu WS, Chien CC, Liu KH, Chen YC and Chiu
WT: Evodiamine prevents glioma growth, induces glioblastoma cell
apoptosis and cell cycle arrest through JNK activation. Am J Chin
Med. 45:879–899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu LH, Xie JY, Guo WW, Wu GY, Chen ZF, Yi
JY, Zhang L, Zhang ZJ and Li Z: Evodiamine activates AMPK and
promotes adiponectin multimerization in 3T3-L1 adipocytes. J Asian
Nat Prod Res. 16:1074–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao T, Zhang X, Zhao Y, Zhang L, Bai X,
Zhang J, Zhao X, Chen L, Wang L and Cui L: Pretreatment by
evodiamine is neuroprotective in cerebral ischemia: Up-regulated
pAkt, pGSK3β, down-regulated NF-κB expression, and ameliorated BBB
permeability. Neurochem Res. 39:1612–1620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pan X, Hartley JM, Hartley JA, White KN,
Wang Z and Bligh SW: Evodiamine, a dual catalytic inhibitor of type
I and II topoisomerases, exhibits enhanced inhibition against
camptothecin resistant cells. Phytomedicine. 19:618–624. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun HZ, Fang ZZ, Cao YF, Sun XY and Hong
M: Investigation of the in vitro metabolism of evodiamine:
Characterization of metabolites and involved cytochrome p450
isoforms. Phytother Res. 27:705–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu JY, Xu ST and Qiu YY: Evodiamine a
novel class of derivatives, their preparation and use. Chinese
patent 201611019652. Filed November. 16:2016.
|
|
26
|
Situ R, Wang HH, Wang JH, He LP, Zhu XL
and Ou WF: Establishment of human brain malignant glioma cell line
(SWO-38) and observation of its biologic properties. Chin J Cancer.
6:235–238. 1987.(In Chinese).
|
|
27
|
Pisapia DJ: The updated world health
organization glioma classification: Cellular and molecular origins
of adult infiltrating gliomas. Arch Pathol Lab Med. 141:1633–1645.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang L, Liang Q, Shen K, Ma L, An N, Deng
W, Fei Z and Liu J: A novel class I histone deacetylase inhibitor,
I-7ab, induces apoptosis and arrests cell cycle progression in
human colorectal cancer cells. Biomed Pharmacother. 71:70–78. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou X, Yue GG, Chan AM, Tsui SK, Fung KP,
Sun H, Pu J and Lau CB: Eriocalyxin B, a novel autophagy inducer,
exerts anti-tumor activity through the suppression of
Akt-mTOR-p70S6K signaling pathway in breast cancer. Biochem
Pharmacol. 142:58–70. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng YC, Hueng DY, Huang HY, Chen JY and
Chen Y: Magnolol and honokiol exert a synergistic anti-tumor effect
through autophagy and apoptosis in human glioblastomas. Oncotarget.
7:29116–29130. 2016.PubMed/NCBI
|
|
31
|
Wang XJ, Chu NY, Wang QH, Liu C, Jiang CG,
Wang XY, Ikejima T and Cheng MS: Newly synthesized
bis-benzimidazole derivatives exerting anti-tumor activity through
induction of apoptosis and autophagy. Bioorg Med Chem Lett.
22:6297–6300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang F, Shi L, Liang T, Ji L, Zhang G,
Shen Y, Zhu F and Xu L: Anti-tumor effect of evodiamine by inducing
Akt-mediated apoptosis in hepatocellular carcinoma. Biochem Biophys
Res Commun. 485:54–61. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eimer S, Belaud-Rotureau MA, Airiau K,
Jeanneteau M, Laharanne E, Véron N, Vital A, Loiseau H, Merlio JP
and Belloc F: Autophagy inhibition cooperates with erlotinib to
induce glioblastoma cell death. Cancer Biol Ther. 11:1017–1027.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kanzawa T, Zhang L, Xiao L, Germano IM,
Kondo Y and Kondo S: Arsenic trioxide induces autophagic cell death
in malignant glioma cells by upregulation of mitochondrial cell
death protein BNIP3. Oncogene. 24:980–991. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang CY, Kuan YH, Ou YC, Li JR, Wu CC,
Pan PH, Chen WY, Huang HY and Chen CJ: Autophagy contributes to
gefitinib-induced glioma cell growth inhibition. Exp Cell Res.
327:102–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grandér D and Panaretakis T: Autophagy:
Cancer therapy's friend or foe? Future Med Chem. 2:285–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu AJ, Wang SH, Chen KC, Kuei HP, Shih
YL, Hou SY, Chiu WT, Hsiao SH and Shih CM: Evodiamine, a plant
alkaloid, induces calcium-JNK-mediated autophagy and
calcium-mitochondria-mediated apoptosis in human glioblastoma
cells. Chem Biol Interact. 205:20–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong G, Sheng C, Wang S, Miao Z, Yao J and
Zhang W: Selection of evodiamine as a novel topoisomerase I
inhibitor by structure-based virtual screening and hit optimization
of evodiamine derivatives as antitumor agents. J Med Chem.
53:7521–7531. 2010. View Article : Google Scholar : PubMed/NCBI
|
